Phil Jobling

Dr. Phil Jobling

School of Biomedical Sciences and Pharmacy, University of Newcastle, 2308 Callaghan, Australia

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Pharmacological Research
Verified
Journal Article
Closed access
NGNathan Griffin
Nathan Griffin
SFSam Faulkner
Sam Faulkner
Phil JoblingPhil Jobling
Phil Jobling
Hubert HondermarckHubert Hondermarck
Hubert Hondermarck

1 February 2016 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
RDRyan J. Duchatel
Ryan J. Duchatel
Phil JoblingPhil Jobling
Phil Jobling
BGBrett A. Graham
Brett A. Graham
LHLauren R. Harms
Lauren R. Harms
PMPatricia T. Michie
Patricia T. Michie
PTPaul A. Tooney
Paul A. Tooney

1 September 2018 in Schizophrenia Research
Verified
Journal Article
Closed access
RDRyan Duchatel
Ryan Duchatel
CMCrystal L. Meehan
Crystal L. Meehan
LHLauren R. Harms
Lauren R. Harms
PMPatricia T. Michie
Patricia T. Michie
MBMark J. Bigland
Mark J. Bigland
PTPaul A. Tooney
Paul A. Tooney

1 June 2008 in Autonomic Neuroscience
Verified
Journal Article
Closed access
Phil JoblingPhil Jobling
Phil Jobling
RLRebecca Lim
Rebecca Lim

1 January 2014 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
Phil JoblingPhil Jobling
Phil Jobling
KOKate O'hara
Kate O'hara
SHSusan Hua
Susan Hua
Pain from the female reproductive tract (FRT) is a significant clinical problem for which there are few effective therapies. The complex neuroantomy of pelvic organs not only makes diagnosis of pelvic pain disorders difficult but represents a challenge to development of targeted therapies. A number of potential therapeutic targets have been identified on sensory neurons supplying the FRT but our knowledge on the basic neurophysiology of these neurons is limited compared with other viscera. Until this is addressed we can only guess if the new experimental therapies proposed for somatic, gastrointestinal or bladder pain will translate to the FRT. Once suitable therapeutic targets become clear, the next challenge is drug delivery. The FRT represents a promising system for topical drug delivery that could be tailored to act locally or systemically depending on formulation. Development of these therapies and their delivery systems will need to be done in concert with more robust in vivo and in vitro models of FRT pain.

1 November 2011 in Autonomic Neuroscience
Verified
Journal Article
Closed access
Phil JoblingPhil Jobling
Phil Jobling